Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

News

The latest news, stories and exciting findings from across the Oxford cancer research community

University's RadCam library highlighted in yellow
Example of H&E staining

Applied mathematical principles help identify immune cell spatial patterns in tumours

A collaboration between mathematicians, pathologists and clinicians has shown how techniques from computational algebraic topology can be used to understand the spatial distributions of immune cell subtypes within tumours.

Two women in the lab with equipment

Six new Fellowships announced as part of Oxford-Bristol Myers Squibb Fellowships Programme

The Oxford - Bristol Myers Squibb (BMS) Fellowships Programme continued to demonstrate significant progress over the last year. Six new Oxford fellowships were announced, including two significant cancer projects.

Oxford cancer clinical trials unit receives acclaimed nursing award

The nursing team at the Early Phase Clinical Trials Unit has been awarded the Excellence in Cancer Research Nursing Award 2021.

Patients and cancer researchers sitting around a table discussing

Haematology workshops enable significant patient involvement

The 'What Matters Most’ initiative was designed as a way of bringing people with Myelodyspastic Syndrome together to talk about their shared experience, and agree a list of priorities for research and service / resource development.

An image of the fungus Cordyceps sinensis. Cordycepin is derived from Cordyceps sinensis, which has been used in traditional Chinese medicine for hundreds of years to treat cancers and other inflammatory diseases. Thanks to this Oxford University-NuCana partnership, a new drug called NUC-7738 has been derived from Cordycepin and is now being tested in clinical trials.

Anti-cancer drug derived from fungus shows promise in clinical trials

A new industry-academic partnership between the University of Oxford and biopharmaceutical company NuCana as found that chemotherapy drug NUC-7738, derived from a Himalayan fungus, has 40 times greater potency for killing cancer cells than its parent compound.

Image of white blood cells attaching a cancer cell

Blood tests may predict response to immunotherapy for melanoma

A study from the Fairfax lab provides new insight into the factors that determine patient response to Immune Checkpoint Blockers, a common immunotherapy treatment for melanoma.

Binary code

Turing Fellowships for Oxford cancer researchers

Oxford Cancer community members will join the Turing network for 2021-2022 to further their research in cancer big data.

A longitudinal section of fetal femur with multiplex immunofluorescent staining, showing CD34 in red and VEGFR2 in green.

New atlas revealed of bone marrow haematopoiesis during development

A new study published this week in Nature, provides the most detailed analysis so far of the prenatal development of blood and immune cells in the bone marrow.

Person holding a test tube with a new drug inside

FOCUS4: a flagship trial in colorectal cancer

Professor Tim Maughan outlines the flagship work of the FOCUS4 trials, whose results were presented this weekend at the European Society of Medical Oncology (ESMO) annual meeting

Chinese alcohol being poured into a glass

Changing drinking patterns in China could drive a major increase in liver diseases

According to new research led by NDPH, Chinese people who regularly drink alcohol have significantly greater risks of developing severe liver diseases, such as cancer.

Woman holding their stomach in pain

New drug shows promise in slowing growth of bowel cancer

The latest results from the multi-arm FOCUS4 trial, led by Tim Maughan at the University of Oxford, has shown that the drug adavosertib has promising activity in bowel cancer patients

Changes in blood cell production over the human lifetime may hold clues to patterns of disease

A new paper published this week in Cell Reports reveals that changes in the gene expression of blood stem cells occur across the human lifetime; an important step in the understanding and treatment of blood cancers.

SYMPLIFY Logo

Oxford to assess revolutionary multi-cancer blood test in trial, for future implementation in the NHS

A partnership between the University of Oxford and GRAIL, LLC will evaluate the use of a new, non-invasive, multi-cancer early detection test known as Galleri in suspected cancer patients.

Lung XRay with a red highlight around a tumour

Oxford Cancer Analytics awarded £1.27M to revolutonise lung cancer management

OXcan, an Oxford University spin out, has raised money to apply their machine learning approach to lung cancer early detection

Vaccination

Vaccine for treating cancer made possible using Oxford COVID vaccine technology

A new publication from Benoit Van den Eynde's group has shown that a viral vector cancer vaccine generates effective anti-tumour immune responses and, in combination with immunotherapy, decreases tumour size and increases survival rates in mouse models.

Blood test tubes

Oxford’s cancer-risk research featured in special edition of PLOS Medicine focussed on advances in early cancer detection

Research from Dr Brian Nicholson and colleagues outlines how routine clinical tests could be widely used to estimate the risk of cancer for people visiting their GPs with unexpected weight loss.

White blood cell surrounded by red blood cells

World Chronic Lymphoid Leukaemia Day 2021

Researchers from Oxford University and OUH are joining celebrations for the first world CLL day on 1 September 2021.

Prostate Cancer Image

Two Oxford immunotherapy research projects awarded funding by Prostate Cancer UK

Prostate Cancer UK have invested £1.7 million into five immunotherapy projects, including two from Profs Kate Vallis, Richard Bryant and Eileen Parkes at the University of Oxford. Read about their funded work.

Lung XRay with a red highlight around a tumour

Oxford spin out partners with J&J to transform lung cancer treatment

Optellum, a lung health start-up in Oxford, aims to redefine early interception of lung cancer using artificial intelligence (AI) decision support software.

NCITA logo

NCITA Publishes Comment Article in the British Journal of Cancer

Read their introduction to the National Cancer Imaging Translational Accelerator (NCITA): a UK-wide infrastructure for multicentre clinical translation of cancer imaging biomarkers.

Load More